CONCURRENCE OF RECURRENT NEPHROLITHIASIS AND BONE SYSTEM LESIONS
The fact that nephrolithiasis is commonly concurrent with varying bone pathology suggests that there is an urgency for publications on bone system lesion in the presence of recurrent nephrolithiasis. Analysis of the pharmacological properties of agents that affect bone may lead to the conclusion that alendronate is beneficial in the treatment of osteoporosis or osteodystrophy in patients with recurrent nephrolithiasis.